United Therapeutics (UTHR) CEO Rothblatt Sells $5.5M of Stock
Key Points
- Martine A Rothblatt, Chairperson and CEO, sold 9,500 shares at a price of $582.76 each, totaling about $5.5 million.
- After this sale, Rothblatt holds 324,443 shares, reducing her stake by about 2.84%.
- The stock recently traded around $592.84, which is about 0.9% above its closing price of $587.50 on the day of the sale.
Since the trade, $UTHR is up 0.9% to date (from the $587.50 close on Oct 23, 2026).
Get United Therapeutics text alerts
We text you when insiders, Congress, analysts or big funds move on $UTHR.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated United Therapeutics Corporation alert may contain errors. Disclosures
Martine A Rothblatt, the Chairperson and CEO of United Therapeutics Corporation (UTHR), sold 9,500 shares on October 23, 2026, for approximately $5.5 million. This transaction was reported in a Form 4 filing with the SEC.
Rothblatt's sale came at a price of $582.76 per share, which is close to the stock's recent trading level. After this sale, she now owns 324,443 shares, cutting her stake by about 2.84%.
UTHR
United Therapeutics Corporation
Other Institutional Activity in United Therapeutics
Avoro Capital Advisors LLC increased its holdings by 147,804 shares, bringing its total to 2,777,777 shares valued at about $1.65 billion. Meanwhile, Renaissance Technologies, LLC trimmed its stake by 78,271 shares, leaving it with 1,708,739 shares worth around $1.01 billion. Jupiter Topco LLC doubled its position, adding 415,564 shares for a total of 831,129 shares valued at about $493 million.
United Therapeutics Corporation Stock Up 1.4%
As of October 26, 2026, United Therapeutics shares recently traded around $592.84, which is about 0.9% above their closing price of $587.50 on October 23. The stock is also 44.9% above its 52-week low of $409.07, but about 2.7% below its 52-week high of $609.35.
Recent Earnings
United Therapeutics reported trailing twelve-month revenue of approximately $3.15 billion, with a net margin of 41.6%. The next earnings report is expected on November 4, 2026.
Insider Buying and Selling at United Therapeutics Corporation
In the days leading up to this sale, Martine A Rothblatt sold 9,500 shares on four separate occasions. On October 19, she sold shares for about $5.2 million, followed by additional sales on October 20 for around $5.3 million, October 21 for about $5.3 million, and October 22 for approximately $5.5 million. All these transactions were planned under a Rule 10b5-1 plan.
Analysts Set New Price Targets
On October 1, 2026, BTIG upgraded its rating on United Therapeutics to "Buy" with a price target of $728.00. Morgan Stanley maintained its "Equal-Weight" rating with a target of $566.00 on October 7, while RBC Capital maintained an "Outperform" rating with a target of $708.00 on October 8. Most recently, RBC Capital adjusted its target to $697.00 on October 22.
About United Therapeutics Corporation
United Therapeutics Corporation develops and commercializes products aimed at meeting the medical needs of patients with chronic and life-threatening conditions. Headquartered in Silver Spring, Maryland, the company focuses on innovative therapies and solutions in the healthcare sector.
Bottom Line
Investors should watch for United Therapeutics' upcoming earnings report on November 4, 2026. Rothblatt's recent sales reflect her ongoing planned trading strategy, which may influence market perceptions of the company's stock.
Related Filing Alerts
Source: Martine A Rothblatt's Form 4 filing on $UTHR (Oct 23, 2026). Written by software, not financial advice. How we make alerts